Historique
Article de Périodique
Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe (2026)
Auteur(s) :
POSE, E. ;
DIAZ, L. A. ;
PARKER, R. ;
ISRAELSEN, M. ;
MARJOT, T. ;
FORREST, E. ;
DHANDA, A. ;
PARADIS, C. ;
ARAB, J. P. ;
KRAG, A. ;
BATALLER, R. ;
MURRAY, F. ;
LAZARUS, J. V. ;
CARRIERI, P. ;
BRENNAN, P. N.
Année
2026
Page(s) :
art. 101707
Langue(s) :
Anglais
Refs biblio. :
94
Domaine :
Alcool
Discipline :
SAN (Santé publique / Public health)
Thésaurus géographique
EUROPE
Thésaurus mots-clés
ALCOOL
;
POLITIQUE
;
DONNEE PROBANTE
;
FOIE
;
REDUCTION DES RISQUES ET DES DOMMAGES
;
MORBIDITE
;
PATHOLOGIE ORGANIQUE
;
CIRRHOSE
;
POPULATION A RISQUE
;
INDUSTRIE DE L'ALCOOL
;
DEPISTAGE
;
RECOMMANDATION
Résumé :
Alcohol-related liver disease (ALD) remains a leading cause of preventable morbidity and mortality in Europe. Despite robust evidence that alcohol-related population-level policies delay use initiation and reduce associated harms, their implementation in Europe has been inconsistent and frequently undermined by alcohol industry interference, fragmented governance, and policy inertia. The burden of ALD as well as combined metabolic dysfunction and alcohol-associated liver disease (MetALD) has grown steadily, driven by increased alcohol intake, widespread metabolic risk factors, delayed diagnosis, and poor integration between primary care, substance use services, endocrinology, and hepatology. In this Series paper, we combine epidemiology, policy evaluations, and clinical evidence to examine these findings through the lenses of policy, system preparedness, education, and stigma. We highlight screening strategies for alcohol use and liver disease and describe models of multidisciplinary and digital care. Finally, we outline priorities for policy reform, stigma reduction, youth-focused prevention, and research on biomarkers, pharmacotherapies, and digital/artificial intelligence tools. [Author's abstract]
Affiliation :
Liver Unit, Hospital Clínic of Barcelona, Fundació Clínic per a la Recerca Biomédica (FCRB) - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain